18 Nov 2014:
The PLOS ONE Staff
Evidence about the efficacy and safety of statin treatment in high-risk patients with hypercholesterolemia is available for some populations, but not for ethnic Chinese. To test the hypothesis that treatment with pitavastatin (2 mg/day) is not inferior to treatment with atorvastatin (10 mg/day) for reducing low-density lipoprotein cholesterol (LDL-C), a 12-week multicenter collaborative randomized parallel-group comparative study of high-risk ethnic Chinese patients with hypercholesterolemia was conducted in Taiwan. In addition, the effects on other lipid parameters, inflammatory markers, insulin-resistance-associated biomarkers and safety were evaluated.
Methods and Results
Between July 2011 and April 2012, 251 patients were screened, 225 (mean age: 58.7 ± 8.6; women 38.2% [86/225]) were randomized and treated with pitavastatin (n = 112) or atorvastatin (n = 113) for 12 weeks. Baseline characteristics in both groups were similar, but after 12 weeks of treatment, LDL-C levels were significantly lower: pitavastatin group = −35.0 ± 14.1% and atorvastatin group = −38.4 ± 12.8% (both: p < 0.001). For the subgroup with diabetes mellitus (DM) (n = 125), LDL-C levels (−37.1 ± 12.9% vs. −38.0 ± 13.1%, p = 0.62) were similarly lowered after either pitavastatin (n = 63) or atorvastatin (n = 62) treatment. Triglycerides, non-high density lipoprotein cholesterol, and apoprotein B were similarly and significantly lower in both treatment groups. In non-lipid profiles, HOMA-IR and insulin levels were higher to a similar degree in both statin groups. Hemoglobin A1C was significantly (p = 0.001) higher in the atorvastatin group but not in the pitavastatin group. Both statins were well tolerated, and both groups had a similar low incidence of treatment-emergent adverse events.
Both pitavastatin (2 mg/day) and atorvastatin (10 mg/day) were well tolerated, lowered LDL-C, and improved the lipid profile to a comparable degree in high-risk Taiwanese patients with hypercholesterolemia.
Citation: Liu P-Y, Lin L-Y, Lin H-J, Hsia C-H, Hung Y-R, et al. (2013) Pitavastatin and Atorvastatin Double-Blind Randomized ComPArative Study among HiGh-Risk Patients, Including ThOse with Type 2 Diabetes Mellitus, in Taiwan (PAPAGO-T Study). PLoS ONE 8(10): e76298. doi:10.1371/journal.pone.0076298
Editor: Stephen L Atkin, Postgraduate Medical Institute & Hull York Medical School, University of Hull, United Kingdom
Received: March 30, 2013; Accepted: August 20, 2013; Published: October 1, 2013
Copyright: © 2013 Liu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Kowa company from Japan funded the medicine for the clinical trial. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: During study period, the Kowa company from Japan funded the medicine for the clinical trial. The authors did not belong to any employment, consultancy, patents, products in development or marketed products, etc. This medicine support did not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Accumulated clinical trials have shown that individuals with elevated low-density lipoprotein cholesterol (LDL-C) have an increased risk of coronary heart disease (CHD); they also report the mortality rates in patients with and without documented CHD [1,2]. Different types of statins are clinically available, but the choice of statin is usually based on its individual pharmacological properties, such as its efficacy for LDL-C reduction and its metabolic dependence on hepatic enzymes.
In addition to LDL-C, some species of triglyceride (TG)-rich lipoproteins are also known to be atherogenic; notable among these are cholesterol-enriched remnant lipoproteins. Moreover, very low-density lipoprotein cholesterol (VLDL-C) is a marker for atherogenic VLDL remnants. Non-high density lipoprotein (non-HDL) cholesterol, which is the sum of VLDL-C and LDL-C, therefore constitutes “atherogenic cholesterol”; it is proposed as a secondary target of lipid-lowering therapy to prevent CHD [3,4].
Type 2 diabetes mellitus (DM) is an important risk factor for developing cardiovascular disease. Type 2 DM has an atherogenic lipid profile consisting of elevated TGs and low HDL-C, which results in high non-HDL-C levels. Thus, a preferable characteristic for an ideal statin to treat metabolic syndrome and dyslipidemia in type 2 DM would be targeted to reduce non-HDL-C and LDL-C, and to elevate HDL-C. The Collaborative Atorvastatin Diabetes Study (CARDS) found that 10 mg daily of atorvastatin, a potent commercial LDL-C-lowering agent, reduced non-HDL-C by 36%  and prevented cardiovascular events in various populations at high risk of arteriosclerotic disease [5,6].
Pitavastatin (2 mg daily, a medium-strength dose) can lower LDL-C by 42% . It was also reported that pitavastatin reduced TGs and remnant lipoprotein cholesterol by 29% and 31%, respectively, and increased HDL-C by 10% in Japanese patients with DM . It also has unique pharmacokinetic properties: although lipophilic, unlike atorvastatin, which is metabolized by CYP3A4, its metabolism is not dependent on cytochrome P450 . In the CHIBA study in Japan, pitavastatin (2 mg daily) was as effective as atorvastatin (10 mg daily) at lowering non-HDL-C by 39.0-40.3% . The efficacy of these two statins was further analyzed in a subgroup of patients with metabolic syndrome. In addition, similar changes were found for total cholesterol (TC) and LDL-C in both treatment groups. HDL-C significantly increased in the pitavastatin group, but not in the atorvastatin group. However, the CHIBA study was an open-label study. It would be interesting to know if the non-HDL-C or LDL-C effect by standard-dose statin treatment may vary on another high-risk Asian population, either with or without type 2 DM.
We tested, in a double-blind study, the hypothesis that pitavastatin (2 mg/day) is not inferior to atorvastatin (10 mg/day) for reducing LDL-C. This collaborative multicenter study ran for 12 weeks with high-risk Taiwanese patients with hypercholesterolemia. In addition, safety, the effects on other lipid parameters, inflammatory markers, and insulin resistance-associated biomarkers, as well as the relationship between lipid-lowering efficacy and body mass index, were evaluated.
All research involving human participants was approved by the authors’ institutional review boards (IRBs) and by the Taiwan Department of Health before the trial began. Informed consent was obtained from all participants, and all clinical investigations were conducted according to the principles expressed in the Declaration of Helsinki.
This Pitavastatin and Atorvastatin randomized comPArative study among hiGh-risk patients including thOse with Type 2 diabetes mellitus in Taiwan (PAPAGO-T study) was a randomized, multicenter, double-blinded, non-inferiority study comparing the efficacy and safety of pitavastatin with that of atorvastatin in high-risk Taiwanese patients with hypercholesterolemia and with or without DM. This trial (NCT01386853) was registered at http://clinicaltrials.gov/ct2/show/NCT01386853?term=NCT01386853&rank=1 . The information for this trial registration is available as supporting information; see Registration Protocol S2.
Patients were recruited from 6 medical centers in Taiwan. After a 4-week dietary lead-in, eligible patients were randomized into 2 equal 12-week treatment groups: Pitavastatin (2 mg/day) (PTV) or Atorvastatin (10 mg/day) (ATV). Patient registration and randomization were done using an interactive voice response system (Virginia Contract Research Organization Co., Ltd., Taipei, Taiwan). The random codes were generated based on permuted block randomization and stratified by type 2 DM status. Statins and fibrates were discontinued during the lead-in period to eliminate any effects of premedication. During the study period, fibrates, other statins, probucol, and cyclosporine  were prohibited. No changes were made in types or doses of permitted lipid-lowering drugs (i.e., eicosapentaenoic acid) or in types or doses of medications used to treat hypertension or diabetes. No changes were made in lifestyle guidance, including exercise and diet, throughout the lead-in and dosing periods.
Eligible patients were men and women aged 20 or older with fasting LDL-C higher than 100 mg/dl. In addition, to be considered “high-risk”, a patient had to meet at least one of the following criteria (NCEP ATP III guideline): 1) documented CHD; 2) type 2 DM; 3) if the patient had fewer than 2 risk factors (other than LDL) present in the following items without CHD or a CHD risk equivalent, a 10-year (short-term) CHD risk had to be assessed with a Framingham score > 20%: [A] female: ≥ 55 years old, or male: ≥ 45 years old; [B] fasting high-density lipoprotein cholesterol (HDL-C) < 40mg/dL; [C] a family history of premature CHD (CHD in first-degree male relative < 55 years; CHD in first-degree female relative < 65 years); [D] hypertension (BP ≥ 140/90 mmHg or treated with anti-hypertensive agents); [E] HDL-C ≥ 60 mg/dL counted as a “negative” risk factor; its presence removed one risk factor from the total count.
Major exclusion criteria, besides the medication prohibitions stated above, were: 1) a history of hypersensitivity to statins; 2) hepatic dysfunction [aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 100 IU/L], suspected hepatic metabolism disorders or biliary obstruction (acute hepatitis, acute exacerbation of chronic hepatitis, liver cirrhosis, liver cancer and jaundice), or renal dysfunction (serum creatinine > 1.5 mg/dL); 3) pregnancy, possible pregnancy, or breastfeeding; 4) poorly controlled diabetes (HbA1C > 9.0%).
The following information was obtained during the dietary lead-in period before randomization: gender, age, height, body weight, menopause (women only), familial hypercholesterolemia, concomitant diseases, past medical history, family history of CHD. Blood samples were collected after overnight fasting. In the follow-up period, blood samples were checked at 4 weeks and 12 weeks. We evaluated the primary efficacy variable in the LDL-C lowering effect as well as the secondary efficacy variable including lipid (both at 4 and 12 weeks) and non-lipid (at 4 weeks) efficacies, such as HDL-C, TG, non-HDL-C, Apo A1, and Apo B levels, and the fasting plasma glucose, fasting insulin, HbA1c, free fatty acid, ADMA, and HOMA-IR parameters.
The primary endpoint was percent change from baseline in LDL-C level after 12 weeks of treatment. Secondary endpoints included percent changes from baseline in TC, TG, and HDL-C. Serum TC, TG, non-HDL-C, and HDL-C levels were measured at one central laboratory.
Patients were diagnosed with type 2 DM if they had fasting plasma glucose ≥ 126 mg/dL or random plasma glucose ≥ 200 mg/dL with classic symptoms, or if they were taking diabetes medication . Safety was assessed from the incidence of adverse events and abnormal laboratory data.
The primary endpoint in the present study was the percentage change in LDL-C. We determined the sample size on the basis of the percentage change in the LDL-C, which is the most commonly used endpoint for assessing the efficacy of statins. For a difference in the mean percentage change in the LDL-C at week 12 between pitavastatin and atorvastatin, standard deviation (SD) of the difference in the mean percentage change of the LDL-C of 14% [14,15], non-inferiority margin of 6%, significance level of 5% in a two-tailed test, and a power level of 80%, the number of patients per group was determined to be 87 (total: 174). Taking into account dropouts, we conducted the present study with 100 patients per group, that is, 200 patients in total. Statistical analysis was done using JMP (SAS Institute, Cary, NC, USA). Numerical data are expressed as mean ± SD and a 95% confidence interval (CI). The ANCOVA was first used to test the difference of LDL-C by incorporating treatment, diabetes mellitus, CHD, and baseline LDL-C. Then, a Wilcoxon rank sum test or a 2-sample t test was used to compare continuous variables between the pitavastatin and atorvastatin groups as the ancillary analyses. A χ2 test was used to analyze categorical data. A 1-sample t test was used to assess the efficacy of each drug at week 12. In all cases, 2-sided tests were done. Efficacy was evaluated based on the intention to treat a general population. For the primary endpoint, there was no significant difference between intention to treat and per protocol analyses.
Of the 251 patients screened between July 2011 and April 2012, finally, 225 (mean age 58.7 ± 8.6; women 38.2% (86/225) were randomly assigned to the PTV (n = 112) or ATV (n = 113) group (Figure 1). The baseline characteristics and parameters for the patients in both groups are shown in Table 1. Subgroup analysis was done for the 125 patients with type 2 DM (PTV group: 63; ATV group: 62).
|Total||Type 2 DM||PTV||ATV||PTV vs. ATV|
|Characteristic||(n = 225)||(n = 125)||(n = 112)||(n = 113)||p-value*|
|Age (years)||58.7 ± 8.6||58.8 ± 8.4||58.7 ± 9.3||58.7 ± 7.9||0.98|
|Male, n (%)||139 (61.8%)||67 (53.6%)||69 (61.6%)||70 (61.9%)||0.95|
|BMI (kg/m2)||26.4 ± 3.5||26.5 ± 3.8||26.6 ± 3.6||26.2 ± 3.4||0.51|
|Body weight (Kg)||69.7 ± 12.2||69.1 ± 13.5||70.8 ± 13.0||68.8 ± 11.4||0.22|
|Systolic pressure (mmHg)||128 ± 15||128 ± 15||127 ± 14||129 ± 16||0.29|
|Diastolic pressure (mmHg)||78 ± 9||77 ± 10||76 ± 9||79 ± 10||0.10|
|Medical history (n (%))|
|Coronary artery disease||78 (34.7%)||16 (12.8%)||38 (33.9%)||40 (35.4%)||0.82|
|Hypertension||17 (75.6%)||88 (70.4%)||85 (75.9%)||85 (75.2%)||0.91|
|Type 2 diabetes mellitus||125 (55.6%)||125 (100%)||62 (55.4%)||63 (55.8%)||0.95|
|Non smoker||184 (81.8%)||104 (83.2%)||94 (83.9%)||90 (79.7%)||0.66|
|Total cholesterol (mg/dL)||213.7 ± 32.3||209.8 ± 31.1||213.0 ± 31.5||214.0 ± 33.1||0.90|
|TG (mg/dL)||154.5 ± 65.6||151.1 ± 67.2||156.0 ± 67||153.0 ± 64.4||0.72|
|LDL-C (mg/dL)||150.4 ± 28.2||146.3 ± 25.6||149.6 ± 26.4||151.2 ± 30||0.66|
|HDL-C (mg/dL)||48.6 ± 10.8||48.7 ± 11.0||48.7 ± 10.8||48.5 ± 10.9||0.89|
|Apo A1 (mg/dL)||136.4 ± 18.8||136.9 ± 19.0||137.0 ± 16.8||136.0 ± 20.7||0.83|
|Apo B (mg/dL)||120.4 ± 20.7||118.0 ± 20.5||120.0 ± 18.7||121.0 ± 22.5||0.83|
|Hemoglobin (g/dL)||14.6 ± 1.4||14.3 ± 1.5||14.6 ± 1.5||14.5 ± 1.4||0.74|
|AST (U/L)||27.1 ± 9.1||28.1 ± 10.5||27.5 ± 10.7||26.8 ± 7.1||0.59|
|ALT (U/L)||31.1 ± 16.6||32.8 ± 18.9||31.5 ± 17.9||30.6 ± 15.1||0.68|
|Gamma GT (U/L)||37.2 ± 32.5||37.4 ± 37.1||37.6 ± 37.0||36.8 ± 27.5||0.87|
|Total bilirubin (mg/dL)||0.8 ± 0.3||0.8 ± 0.3||0.8 ± 0.3||0.8 ± 0.3||0.36|
|BUN (mg/dL)||15.7 ± 3.7||16.0 ± 3.9||15.7 ± 3.6||15.7 ± 3.9||1.00|
|Creatinine (mg/dL)||0.84 ± 0.22||0.8 ± 0.20||0.84 ± 0.24||0.83 ± 0.19||0.74|
|hsCRP (mg/dL)||0.25 ± 0.80||0.33 ± 1.05||0.17 ± 0.23||0.33 ± 1.1||0.13|
|CPK (U/L)||128.0 ± 73||125.0 ± 71||125.0 ± 65||131.0 ± 81||0.58|
|LDH (U/L)||193.0 ± 35||195.0 ± 37||192.0 ± 32||194.0 ± 38||0.70|
|Fatty acid (mmol/L)||1.0 ± 0.5||1.1 ± 0.5||1.0 ± 0.5||1.0 ± 0.6||0.85|
|ADMA (μmol/L)||0.58 ± 0.13||0.59 ± 0.13||0.58 ± 0.13||0.59 ± 0.13||0.55|
|Fasting glucose (mg/dL)||115.3 ± 25||129.6 ± 24.6||117.0 ± 26.8||114.0 ± 23.1||0.14|
|HbA1C (%)||6.5 ± 0.8||7.0 ± 0.8||6.5 ± 0.9||6.5 ± 0.8||0.41|
|Insulin (μU/ml)||12.6 ± 7.8||12.9 ± 8.2||13.1 ± 8.2||12.1 ± 7.5||0.35|
|HOMA-IR||3.7 ± 2.8||4.2 ± 3.3||3.9 ± 3.3||3.4 ± 2.3||0.15|
There was no significant difference in the primary end point: percentage change in the LDL-C level from baseline between the PTV and ATV groups. LDL-C levels were significantly lower in both groups after 12 weeks of treatment: PTV by −35.0 ± 14.1% and ATV by −38.4 ± 12.8% (both p < 0.001) (Table 2 and Figure 2). The values and percentage changes from baseline in HDL-C, TG, non-HDL-C, Apo A1, and Apo B (secondary endpoints) are shown in Table 2 and Figure 2; the results of intergroup comparison were comparable. The available lipid profiles for LDL-C, HDL-C, TG, and non-HDL-C were similar between weeks 4 and 12, which indicated no time-effect between week 4 and the end of the study. Furthermore, both pitavastatin and atorvastatin significantly reduced TG (−18.1 ± 32.9% vs. −19.1 ± 26.4%, both p < 0.0001), non-HDL-C (−34.8 ± 11.9% vs. −36.6 ± 10.8%, both p < 0.0001), and Apo B (−26.1 ± 11.9% vs. −30.1 ± 14.0%, both p < 0.0001). Neither had any significant effect on HDL-C levels (−1.7 ± 11.9% vs. −1.8 ± 11.5%, both p > 0.05) or Apo A1 levels (+0.6 ± 14.3% vs. −0.2 ± 9.4%, both p > 0.05).
|Baseline||4 weeks||12 weeks||Percentage change (%)#||Baseline vs. week 12 p-value|
|Total cholesterol (mg/dL)|
|PTV||213.0 ± 31.5||155.7 ± 27.1||154.9 ± 28.4||−27.3 ± 10.0||< 0.001|
|ATV||214.0 ± 33.1||155.0 ± 29.0||152.0 ± 28.3||−28.7 ± 9.1||< 0.001|
|PTV||156.0 ± 67||118.9 ± 51.4||118.4 ± 51.3||−18.1 ± 32.9||< 0.001|
|ATV||153.0 ± 64.4||117.9 ± 50.3||116.4 ± 49.7||−19.1 ± 26.4||< 0.001|
|PTV||149.6 ± 26.4||96.5 ± 26.1||97.2 ± 26.9||−35.0 ± 14.1||< 0.001|
|ATV||151.2 ± 30||95.0 ± 25.8||92.8 ± 26.0||−38.4 ± 12.8||< 0.001|
|PTV||48.7 ± 10.8||47.8 ± 10.6||47.6 ± 10.4||−1.7 ± 11.9||0.13|
|ATV||48.5 ± 10.9||48.0 ± 10.3||47.4 ± 10.7||−1.8 ± 11.5||0.10|
|Apo A1 (mg/dL)|
|PTV||137.0 ± 16.8||NA||136.9 ± 23.7||0.6 ± 14.3||0.45|
|ATV||136.0 ± 20.7||NA||134.9 ± 17.7||−0.2 ± 9.4||0.79|
|Apo B (mg/dL)|
|PTV||120.0 ± 18.7||NA||88.9 ± 26.0||−26.1 ± 11.9||< 0.001|
|ATV||121.0 ± 22.5||NA||83.8 ± 22.1||−30.1 ± 14.0||< 0.001|
There is no significant difference in the percentage change of low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), triglyceride (TG), non-HDL-C, apolipoprotein A1 (Apo A1), or apolipoprotein B (Apo B) levels from baseline, between the PTV and ATV groups. Both statins similarly but significantly reduced LDL-C levels after 12 weeks of treatment. PTV and ATV significantly reduced TG, non-HDL-C, and Apo B; the percentage changes were not significantly different.
To compare the lipid-lowering effects of these 2 statins on the DM (n = 125) and non-DM (n = 100) subgroups, we calculated the percentage of patients who achieved target LDL-C levels (< 100 mg/dL) at the end of treatment. The effects were similar for both statins (both p > 0.05) for patients with and without type 2 DM (Table 3).
|Type 2 DM−||Type 2 DM+|
|(n = 50)||(n = 50)||p-value||(n = 62)||(n = 63)|
|Achieved LDL-C goal, n (%)||25 (50%)||33 (66%)||0.11||42 (67.8%)||44 (69.8%)||0.8|
Table 4 shows the non-lipid profiles of values and percentage changes from baseline in glucose, insulin, HOMA-IR, fatty acid, HbA 1C, and ADMA levels (secondary endpoints), and the results of intergroup comparison. Fasting glucose (PTV: +4.8 ± 18.1, p = 0.006; ATV: +4.8 ± 17.0%, p = 0.003), insulin (PTV: +24.8 ± 83.9%, p = 0.002; ATV: +17.9 ± 48.7%, p = 0.002), HOMA-IR (PTV: +33.8 ± 97.4%, p = 0.0004; ATV: +26.5 ± 63.5%, p < 0.0001), ADMA (PTV: +11.2 ± 37.1%, p = 0.002; ATV: +15.1 ± 72.2%, p = 0.03), and fatty acids (PTV: +18.9 ± 99.1%, p = 0.05; ATV: +15.5 ± 80.5%, p = 0.04) were all similarly and significantly higher in both groups. Interestingly, although glucose and insulin levels were higher in both groups, the HbA 1C level was significantly higher (+1.6 ± 5.2%, p = 0.001) in the ATV group but not in the PTV group (+0.8 ± 7.8%, p = 0.27).
|Baseline||12 weeks||Percentage change (%)#||Baseline vs. week 12 p-value|
|PTV||117.1 ± 26.8||123.0 ± 38.2||4.8 ± 18.1||0.006|
|ATV||113.5 ± 23.1||119.1 ± 33.3||4.8 ± 17.0||0.003|
|PTV||13.1 ± 8.2||15.0 ± 11.0||24.8 ± 83.9||0.002|
|ATV||12.1 ± 7.5||12.7 ± 7.3||17.9 ± 48.7||0.0002|
|PTV||3.9 ± 3.3||4.9 ± 5.1||33.8 ± 97.4||0.0004|
|ATV||3.4 ± 2.3||3.8 ± 2.6||26.5 ± 63.5||< 0.0001|
|Fatty acid [mmol/L]|
|PTV||1.02 ± 0.53||1.01 ± 0.7||−18.9 ± 99.1||0.05|
|ATV||1.04 ± 0.57||0.99 ± 0.59||−15.5 ± 80.5||0.04|
|PTV||6.5 ± 0.9||6.5 ± 1.1||0.8 ± 7.8||0.27|
|ATV||6.5 ± 0.8||6.6 ± 1.0||1.6 ± 5.2||0.001|
|PTV||0.58 ± 0.13||0.62 ± 0.17||11.2 ± 37.1||0.002|
|ATV||0.59 ± 0.13||0.65 ± 0.40||15.1 ± 72.2||0.03|
Safety and Tolerability
Both pitavastatin and atorvastatin were well tolerated, and patients in both groups experienced a similar incidence (PVT: 17 events; AVT: 21 events) of treatment-emergent adverse events (Table 5). The frequency difference between treatment groups was minor and most of the treatment-related adverse events were moderate or minor. However, there were 7 serious adverse events (SAE) reported in this study. One patient accidentally choked to death on his breakfast at the end of week 7; this event was not related to the medication. One patient had diverticulitis, a moderately severe SAE; this was related to the study medication treatment. The patient was withdrawn from the study and recovered without sequelae. In addition, two patients failed to take 75% of their total study medications: one patient forgot to take 16 capsules on visits 2-5, and another patient forgot to take 8 capsules on visits 3-5.
|(n = 112)||(n = 113)|
|n (%)||n (%)|
|Adverse drug reaction|
|Myalgia||1 (0.9)||2 (1.8)|
|Back pain||2 (1.8)||3 (2.7)|
|Skin rash||1 (0.9)||0 (0)|
|Sleep disorder||0 (0)||0 (0)|
|Anxiety||1 (0.9)||0 (0)|
|Upper airway infection||4 (3.5)||6 (5.3)|
|Nasopharyngitis||6 (5.3)||6 (5.3)|
|Cough||2 (1.8)||5 (4.4)|
Most of the clinical and laboratory safety results analyzed at baseline and after treatment and most of the evaluation results showed minor changes (Table 6). The hsCRP levels were lower in the PTV group (−28.6 ± 157.4%, p = 0.08) than in the ATV group (−10.8 ± 124.9%, p = 0.38). Although the levels of the parameters were similar before and after treatment between the two treatment groups, the creatine phosphokinase (CPK) (+17.8 ± 45.8%, p = 0.0001), ALT (+10.5 ± 39.9%, p = 0.008), and gamma glutamyl transpeptidase (GT) values (+6.2 ± 32.3%, p = 0.05) were significantly higher in the ATV group, but the change in the PTV group was not significant. More interestingly, the total bilirubin level was unchanged in the PTV group (−0.9 ± 31.8%, p = 0.77) but significantly higher in the ATV group (+14.0 ± 43.0% p = 0.001), which indicated completely different effects on total bilirubin level between the statin treatments (changes by pitavastatin vs. changes by atorvastatin treatment, p < 0.001).
|Baseline||Week 12||Percentage change (%)#||Baseline vs. week 12 p-value|
|PTV||0.17 ± 0.2||0.14 ± 0.21||−28.6 ± 157.4||0.08|
|ATV||0.33 ± 1.1||0.19 ± 0.38||−10.8 ± 124.9||0.38|
|PTV||125.4 ± 64.6||153.2 ± 252.7||22.3 ± 140.6||0.13|
|ATV||130.9 ± 81.1||142.7 ± 90.8||17.8 ± 45.8||0.0001|
|PTV||27.5 ± 10.7||28.3 ± 13.6||5.9 ± 29.3||0.05|
|ATV||26.8 ± 7.1||27.4 ± 8.5||4.5 ± 24.9||0.07|
|PTV||31.5 ± 17.9||32.1 ± 19.5||6.7 ± 33.8||0.06|
|ATV||30.6 ± 15.1||31.1 ± 14.3||10.5 ± 39.9||0.008|
|Gamma GT [U/L]|
|PTV||37.6 ± 37||34.8 ± 25.6||−5.6 ± 29.9||0.07|
|ATV||36.8 ± 27.5||37. ± 27.1||6.2 ± 32.3||0.05|
|Total bilirubin [mg/dL]**|
|PTV||0.8 ± 0.3||0.7 ± 0.3||−0.9 ± 31.8||0.77|
|ATV||0.8 ± 0.3||0.9 ± 0.4||14.0 ± 43.0||0.001|
|PTV||15.7 ± 3.6||16.4 ± 4.0||5.2 ± 22.0||0.02|
|ATV||15.7 ± 3.9||16.1 ± 4.5||4.2 ± 19.8||0.03|
|Serum creatinine [mg/dL]|
|PTV||0.8 ± 0.2||0.8 ± 0.2||−1.2 ± 9.9||0.24|
|ATV||0.8 ± 0.2||0.8 ± 0.2||−0.7 ± 10.7||0.54|
|PTV||192.0 ± 31.7||189.7 ± 33.8||−0.3 ± 14.6||0.84|
|ATV||193.8 ± 38.4||195.3 ± 47.7||1.3 ± 17.9||0.45|
In summary, the differences in clinical and laboratory results between the PTV and ATV groups were mostly nonsignificant. The safety evaluation difference between pitavastatin treatment and atorvastatin treatment was minor.
Subgroup analysis in DM patients
Our original aim was to test the comparative effect between the 2 statins in high-risk patients. However, considering the clinical importance and potential impact of type 2 DM on cardiovascular risk, we distributed patients with and without type 2 DM equally during randomization. There was no significant difference in the lipid lowering effect in the groups stratified by type 2 DM status. Finally, a subgroup analysis showed no significant post-treatment differences in LDL-C levels (Figure 3).
Continuous variables are means ± SD. ADMA = asymmetric dimethylarginine; ALT = alanine aminotransferase; Apo A1 = apolipoprotein A1; Apo B = apolipoprotein B; AST = aspartate transaminase; BMI = body mass index; BUN = blood urea nitrogen; CPK = creatine phosphokinase; CRP = C-reactive protein; DM = Diabetes mellitus; Gamma GT = gamma-glutamyl transpeptidase; HDL-C = high-density lipoprotein cholesterol; HOMA-IR = homeostatic model assessment-insulin resistance; LDH = lactate dehydrogenase; LDL-C = low-density lipoprotein cholesterol; TG = triglyceride.
This is the first prospective clinical study that directly compared the efficacy of low-dose pitavastatin and atorvastatin for a high-risk population in Taiwan. Twelve weeks of treatment with pitavastatin (2 mg) or atorvastatin (10 mg) significantly lowered LDL-C, TG, non-HDL-C, and Apo B to a similar extent without serious drug-treatment-emergent adverse effects. Our findings support the clinical utility and universal efficacy of pitavastatin in high-risk patients with hypercholesterolemia, including those with type 2 DM.
LDL-C lowering effect
The CHIBA  study was the first on Japanese patients with metabolic syndrome and a significantly higher-than-normal BMI (mean value: 31.1). In the present study, the average reduction in LDL-C was approximately 35-38% for both the PTV and ATV groups, in patient cohorts at high risk for cardiovascular events, which is comparable to the value reported in the CHIBA study. Furthermore, in a recent meta-analysis , there was a trend of LDL-C reduction similar to that shown in our study cohort. The meta-analysis included clinical trials comparing the lipid-profile-lowering effect of standard doses of pitavastatin and atorvastatin. Interestingly, a very similar LDL-C lowering effect was observed (−38 to −44% with pitavastatin (2 mg) and −38 to −45% with atorvastatin (10 mg)). It seems that the LDL-C lowering effects may be similar with either standard dose pitavastatin or atorvastatin universally across different patient cohorts.
HDL-C modifying effect
One in vitro study  suggested that, compared with atorvastatin, pitavastatin might increase the production of Apo A1, an essential component of the HDL-C particle, in HepG2 cells at lower concentrations. Moreover, pitavastatin stimulates lipoprotein lipase (LPL) activity more potently than does atorvastatin, which may facilitate an increase in HDL-C through the efficient metabolism of TG-rich lipoproteins . However, in the CIRCLE study , there was a significantly different outcome only in patients with lower baseline HDL-C (< 45 mg/dL) levels. The high-risk cohort in the present study had a relatively higher level of baseline HDL-C (48.5 to 48.7 mg/dL), which might partially explain the insignificant difference in the change in the HDL-C level. However, the HDL-C level tended to increase with treatment when the baseline level was < 45 mg/dL. Taken together, it seems that these statins might more effectively raise HDL-C levels in patients with a lower rather than a higher baseline HDL-C level. The above might have potential clinical impact, because the average level of HDL-C is usually < 45 mg/dL in general, and even < 40 mg/dL with type 2 DM in patients in Taiwan with stroke or myocardial infarction [20, 21].
Glucose metabolic profile
In this high-risk cohort, the glucose metabolism change was particularly intriguing. We found that both statins nonsignificantly increased glucose, insulin, HOMA-IR, and ADMA levels. Interestingly, while unchanged in the PTV group, the level of HbA1c was significantly higher in the ATV group. Our results thus support the notion that these two statins have different therapeutic effects on glucose metabolism. Additional studies are still required to elucidate the mechanisms for the discrepancy in effects on insulin, HOMA-IR, and HbA 1C. In this regard, some issues may be further mentioned. Firstly, patients with and without type 2 DM were enrolled in the present study. In those with type 2 DM, it could be controversial to evaluate the insulin sensitivity by HOMA-IR and insulin level in the presence of hypoglycemic agents. Secondly, in previous cohort studies [22,23], it took years to evaluate the potential effects of statin treatment on new-onset type 2 DM and deteriorated glucose control. The observation period may be not long enough for consistent changes in glucose metabolism, including both HOMA-IR and HbA 1C in the current study. Interestingly, pitavastatin increases LPL expression in 3T3-L1 pre-adipocytes in vitro . LPL activity is crucial in VLDL and remnant lipoprotein metabolism, and is often suppressed in the presence of insulin resistance . It was suggested in the CHIBA study that pitavastatin may facilitate remnant lipoprotein catabolism by upregulating LPL activity in Japanese patients with metabolic syndrome . In the current study, we did not investigate the LPL activity. Future long-term effects of pitavastatin on glucose metabolism should be investigated to show their potential clinical impact on this high-risk cohort.
Safety and tolerability
Throughout this study, both pitavastatin and atorvastatin treatments were well tolerated, and neither of the drugs induced severe adverse reactions, such as rhabdomyolysis, which reflected previous findings that serious adverse events caused by statin treatment are rare. The hsCRP, AST, and gamma GT levels were not significantly different before and after treatment. However, the post-treatment CPK, ALT, and total bilirubin values were all significantly higher in the ATV group but not in the PTV group. During this clinical trial, compared with baseline, the total bilirubin level nonsignificantly decreased in the PTV group but significantly increased in the ATV group. These changes in liver function profiles are partially explained by their metabolic pathways. Pitavastatin and atorvastatin are known to be metabolized via different pathways in the intestine and the liver. In contrast to atorvastatin, which is metabolized primarily by CYP3A4, only a small fraction of pitavastatin is metabolized by CYP2C9 . One study showed that the maximum concentrations in plasma as well as the area under the plasma-concentration curve of atorvastatin were affected by drinking grapefruit juice (a CYP3A4 inhibitor), whereas these parameters for pitavastatin were mostly unaffected . Moreover, when atorvastatin or pitavastatin were added to HepG2 cells at doses that inhibit cholesterol synthesis to comparable levels, the extent of increase in LDL receptor mRNA was significantly larger in the PTV group than in the ATV group . These results suggest that pitavastatin may eliminate cholesterol from blood circulation without excessively hindering cholesterol synthesis in the liver .
Limitations of this study are that the treatment period was relatively short (12 weeks) and the sample size was small; therefore, the long-term safety as well as the protective effect of the two statins against cardiovascular diseases could not be evaluated. Trials with more patients and a longer follow-up period are needed to prove the clinical usefulness of pitavastatin.
In conclusion, both pitavastatin (2 mg) and atorvastatin (10 mg) were well tolerated, lowered LDL-C, and improved the lipid profile to a comparable degree in high-risk Taiwanese patients with hypercholesterolemia with and without comorbid type 2 DM.
We thank Chin-Chou Huang, MD, and Wen-Chung Yu, MD, of Taipei Veterans General Hospital; Chia-Lun Chao, MD, Ta-Chen Su, MD, and Hung-Ju Lin, MD, of National Taiwan University Hospital; Chang-Hsun Hsieh, MD, Chih-Tsueng He, MD, Ling-Yi Wu, MD, and Fone-Ching Hsiao, MD, of Tri-Service General Hospital; Yi-Heng Li, MD, Wei-Chuan Tsai, MD, Ting-Hsing Chao, MD, Ju-Yi Chen, MD, Cheng-Han Lee, MD, Chih-Chan Lin, MD, Shih-Hung Chan, MD, Po-Sheng Chen, MD, Yen-Wen Liu, MD, and Wei-Ting Li, MD, of National Cheng Kung University Hospital; Lee-Shin Lin, MD, and Po-Ching Chi, MD, of Changhua Christian Hospital; Ta-Chuan Hung, MD, Jen-Yuan Kuo, MD, and Cheng-Huang Su, MD, of Mackay Memorial Hospital, for their invaluable advice and assistance.
Kuo-Liong Chien and Jaw-Wen Chen take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.
Conceived and designed the experiments: KLC JWC. Performed the experiments: PYL LYL HJL CHH YRH HIY TCW JYC KLC JWC. Analyzed the data: PYL LYL HJL CHH YRH HIY TCW JYC KLC JWC. Contributed reagents/materials/analysis tools: KLC JWC PYL LYL HJL. Wrote the manuscript: PYL LYL.
- 1. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR et al. (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333: 1301-1307. doi:10.1056/NEJM199511163332001. PubMed: 7566020.
- 2. (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389. PubMed: 7968073.
- 3. Lu W, Resnick HE, Jablonski KA, Jones KL, Jain AK et al. (2003) Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. Diabetes Care 26: 16-23. doi:10.2337/diacare.26.1.16. PubMed: 12502653.
- 4. Panel Expert Detection on, Evaluation , and Treatment of High Blood Cholesterol in Adults (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285: 2486-2497. doi:10.1001/jama.285.19.2486. PubMed: 11368702.
- 5. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA et al. (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364: 685-696. doi:10.1016/S0140-6736(04)16895-5. PubMed: 15325833.
- 6. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G et al. (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361: 1149-1158. doi:10.1016/S0140-6736(03)12948-0. PubMed: 12686036.
- 7. Saito Y, Yamada N, Teramoto T, Itakura H, Hata Y et al. (2002) Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Dose-finding study using the double-blind, three-group parallel comparison. Arzneimittelforschung 52: 251-255. PubMed: 12040967.
- 8. Sone H, Takahashi A, Shimano H, Ishibashi S, Yoshino G et al. (2002) HMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with type-2 diabetes. Life Sci 71: 2403-2412. doi:10.1016/S0024-3205(02)02038-6. PubMed: 12231401.
- 9. Fujino H, Yamada I, Shimada S, Nagao T, Yoneda M (2002) Metabolic fate of pitavastatin (NK-104), a new inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase. Effects on drug-metabolizing systems in rats and humans. Arzneimittelforschung 52: 745-753. PubMed: 12442637.
- 10. Yokote K, Bujo H, Hanaoka H, Shinomiya M, Mikami K et al. (2008) Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis 201: 345-352. doi:10.1016/j.atherosclerosis.2008.02.008. PubMed: 18472103.
- 11. Chen JW (2011) 12-week, randomized, multicenter, double-blind, active-controlled, non-inferiority study to compare the efficacy and safety of pitavastatin and atorvastatin (High risk hypercholesterolemic patients as efficacy and safety study of pitavastatin and atorvastatin in high risk hypercholesterolemic patients, NCT01386853). Available: http://clinicaltrials.gov/. Accessed 2013 September 26.
- 12. Fujino H, Nakai D, Nakagomi R, Saito M, Tokui T et al. (2004) Metabolic stability and uptake by human hepatocytes of pitavastatin, a new inhibitor of HMG-CoA reductase. Arzneimittelforschung 54: 382-388. PubMed: 15344842.
- 13. Kuzuya T, Nakagawa S, Satoh J, Kanazawa Y, Iwamoto Y et al. (2002) Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract 55: 65-85. doi:10.1016/S0168-8227(01)00365-5. PubMed: 11755481.
- 14. Teramoto T, Saito Y, Yamada N et al. (2001) Clinical safety and efficacy of NK-104 (Pitavastatin), a new synthetic HMG-CoA reductase inhibitor, in the long-term treatment of hyperlipidemia—results of a multicenter long-term study. Clin Ther Med 17: 885-913 [ in Japanese]. doi: 10.1016/0021-9150(94)93674-9
- 15. Japan Cholesterol Lowering Atorvastatin Study (J-CLAS) Group (1999) Clinical effect of the novel HMG-CoA reductase inhibitor CI-981 (atorvastatin) in long-term treatment. Prog Med 19: 2123-60 [ in Japanese].
- 16. Poolsup N, Suksomboon N, Wongyaowarat K, Rungkanchananon B, Niyomrat P et al. (2012) Meta-analysis of the comparative efficacy and safety of pitavastatin and atorvastatin in patients with dyslipidaemia. J Clin Pharm Ther 37: 166-172. doi:10.1111/j.1365-2710.2011.01274.x. PubMed: 21585411.
- 17. Maejima T, Yamazaki H, Aoki T, Tamaki T, Sato F et al. (2004) Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell. Biochem Biophys Res Commun 324: 835-839. doi:10.1016/j.bbrc.2004.09.122. PubMed: 15474503.
- 18. Saiki A, Murano T, Watanabe F, Oyama T, Miyashita Y et al. (2005) Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes. J Atheroscler Thromb 12: 163-168. doi:10.5551/jat.12.163. PubMed: 16020917.
- 19. Maruyama T, Takada M, Nishibori Y, Fujita K, Miki K et al. (2011) Comparison of preventive effect on cardiovascular events with different statins. − The CIRCLE study. Circ J 75: 1951-1959. doi:10.1253/circj.CJ-10-1163. PubMed: 21673458.
- 20. Li CY, Wang HF, Chen SY, Chen YT, Chiang YY et al. (2012) High risk for future events in acute stroke patients with an ankle-brachial index less than 0.9. Acta Cardiol Sin 28:17-24.
- 21. Hsu HP, Jou YL, Lin SJ, Charng MJ, Chen YH et al. (2011) Comparison of in-hospital outcome of acute ST elevation myocardial infarction in patients with versus without diabetes mellitus. Acta Cardiol Sin 27: 145-151.
- 22. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM et al. (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359: 2195-2207. doi:10.1056/NEJMoa0807646. PubMed: 18997196.
- 23. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM et al. (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375: 735-742. doi:10.1016/S0140-6736(09)61965-6. PubMed: 20167359.
- 24. Hanyu O, Miida T, Obayashi K, Ikarashi T, Soda S et al. (2004) Lipoprotein lipase (LPL) mass in preheparin serum reflects insulin sensitivity. Atherosclerosis 174: 385-390. doi:10.1016/j.atherosclerosis.2004.01.034. PubMed: 15136071.
- 25. Ando H, Tsuruoka S, Yanagihara H, Sugimoto K, Miyata M et al. (2005) Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. Br J Clin Pharmacol 60: 494-497. doi:10.1111/j.1365-2125.2005.02462.x. PubMed: 16236039.
- 26. Morikawa S, Umetani M, Nakagawa S, Yamazaki H, Suganami H et al. (2000) Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. J Atheroscler Thromb 7: 138-144. PubMed: 11480454.
- 27. Egawa T, Toda K, Nemoto Y, Ono M, Akisaw N et al. (2003) Pitavastatin ameliorates severe hepatic steatosis in aromatase-deficient (Ar-/-) mice. Lipids 38: 519-523. doi:10.1007/s11745-003-1093-x. PubMed: 12880107.